Search results
Royal Bank of Canada Increases Moderna (NASDAQ:MRNA) Price Target to $135.00
ETF DAILY NEWS· 6 hours agoModerna (NASDAQ:MRNA – Get Free Report) had its target price lifted by Royal Bank of Canada from $125.00 to $135.00 in a report...Friday, Benzinga reports. Royal Bank of Canada ...
Mission Wealth Management LP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 6 hours agoMission Wealth Management LP bought a new position in Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities ...
mRNA Is Promising A Breakthrough In Fighting Cancer
Benzinga via Yahoo Finance· 6 days agoWhen it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 3 days agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 3 days agoThis means Moderna stock outranks nearly three-quarters of all stocks on that metric. But MRNA stock...
Morgan Stanley Raises Pfizer (NYSE:PFE) Price Target to $29.00
ETF DAILY NEWS· 4 hours agoPfizer (NYSE:PFE – Free Report) had its price target boosted by Morgan Stanley from $28.00 to $29.00 in a research report report published on Thursday, Benzinga reports. They currently have ...
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Zacks via Yahoo Finance· 3 days agoOver the past six months, shares of MRNA have risen 46.27%. (See the last biotech stock roundup...
J.P. Morgan downgrades Metagenomi over Moderna deal termination (NASDAQ:MGX)
Seeking Alpha· 3 days agoJ.P. Morgan has lowered its rating of Metagenomi (NASDAQ:MGX) to neutral, citing the recent...
Pfizer (NYSE:PFE) Earns Outperform Rating from BMO Capital Markets
ETF DAILY NEWS· 4 hours agoBMO Capital Markets currently has a $36.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $33.00. Cantor Fitzgerald restated an ...
Quiver Morning News By Quiver Quantitative
Investing.com· 3 days agoQuiver Morning News